PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-16.04%
Negative revenue growth while CVE stands at 12.69%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-35.12%
Negative gross profit growth while CVE is at 471.35%. Joel Greenblatt would examine cost competitiveness or demand decline.
-142.19%
Negative EBIT growth while CVE is at 288.97%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-142.19%
Negative operating income growth while CVE is at 288.97%. Joel Greenblatt would press for urgent turnaround measures.
-188.64%
Negative net income growth while CVE stands at 136.25%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-188.65%
Negative EPS growth while CVE is at 136.67%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-188.65%
Negative diluted EPS growth while CVE is at 136.67%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.69%
Dividend growth above 1.5x CVE's 2.44%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
6.99%
Positive OCF growth while CVE is negative. John Neff would see this as a clear operational advantage vs. the competitor.
-710.53%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-78.32%
Negative 10Y revenue/share CAGR while CVE stands at 72.56%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-71.35%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-50.31%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-87.61%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-84.62%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-62.95%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-144.94%
Negative 10Y net income/share CAGR while CVE is at 184.17%. Joel Greenblatt sees a major red flag in long-term profit erosion.
2.01%
Positive 5Y CAGR while CVE is negative. John Neff might view this as a strong mid-term relative advantage.
3.70%
Below 50% of CVE's 242.32%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
-63.08%
Negative equity/share CAGR over 10 years while CVE stands at 8.71%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-67.81%
Negative 5Y equity/share growth while CVE is at 11.55%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
2.38%
Below 50% of CVE's 5.71%. Michael Burry suspects a serious short-term disadvantage in building book value.
-81.06%
Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.
-91.83%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-69.12%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
-33.40%
Firm’s AR is declining while CVE shows 20.35%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
0.52%
Asset growth well under 50% of CVE's 3.20%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-1.70%
We have a declining book value while CVE shows 1.39%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
0.09%
Debt shrinking faster vs. CVE's 2.39%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
No Data
No Data available this quarter, please select a different quarter.
-9.90%
We cut SG&A while CVE invests at 42.25%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.